Interleukin II (60-70) Mechanism, Clinical Value, and Resear

Interleukin II (60-70): Mechanism, Clinical Value, and Research Perspectives in Immunomodulation
Introduction [Related: rsl3 gpx4 inhibitor]
Interleukin II (60-70) is a synthetic peptide fragment derived from the human cytokine Interleukin-2 (IL-2), specifically encompassing amino acid residues 60 to 70. As a bioactive segment of IL-2, this peptide has garnered significant interest for its immunomodulatory properties, particularly in the context of T-cell activation and proliferation. IL-2 itself is a pivotal cytokine in the regulation of immune responses, playing a crucial role in the growth, differentiation, and survival of antigen-selected cytotoxic T cells (Smith, 1988, Science). The 60-70 region of IL-2 has been identified as a functional domain involved in receptor binding and signal transduction, making Interleukin II (60-70) a valuable tool for dissecting IL-2-mediated pathways and for potential therapeutic applications in immunology and oncology. Mechanistically, Interleukin II (60-70) interacts with the IL-2 receptor (IL-2R) complex, which comprises three subunits: α (CD25), β (CD122), and γ (CD132). The peptide mimics the natural ligand’s ability to engage the receptor, thereby modulating downstream signaling cascades such as the JAK/STAT, PI3K/Akt, and MAPK pathways (Waldmann, 2006, Nat Rev Immunol). This selective modulation offers a unique approach to fine-tuning immune responses, which is particularly relevant in diseases characterized by immune dysregulation. [Related: 2 3 cgamp]
Clinical Value and Applications [Related: y27632 molecular weight]
The clinical value of Interleukin II (60-70) lies in its capacity to modulate immune cell activity with greater specificity and potentially reduced toxicity compared to full-length IL-2. Traditional recombinant IL-2 therapy, while effective in certain cancers such as metastatic melanoma and renal cell carcinoma, is often limited by severe adverse effects, including capillary leak syndrome and systemic inflammation (Atkins et al., 1999, J Clin Oncol). The use of peptide fragments like Interleukin II (60-70) aims to retain the immunostimulatory benefits of IL-2 while minimizing off-target effects. In preclinical and translational research, Interleukin II (60-70) serves as a valuable probe for studying IL-2 receptor interactions, T-cell activation thresholds, and the modulation of regulatory T cells (Tregs). Its application extends to the development of novel immunotherapeutic strategies, including cancer immunotherapy, vaccine adjuvant design, and the treatment of autoimmune disorders. By targeting specific receptor subunits or signaling motifs, Interleukin II (60-70) may facilitate the selective expansion of effector T cells or the suppression of Tregs, depending on the disease context (Boyman & Sprent, 2012, Nat Rev Immunol).
Key Challenges and Pain Points Addressed
Current immunotherapies leveraging full-length IL-2 face several challenges, including: 1. **Toxicity and Systemic Side Effects:** High-dose IL-2 therapy is associated with significant adverse events, limiting its clinical utility (Rosenberg et al., 1994, N Engl J Med). 2. **Lack of Selectivity:** IL-2 can stimulate both effector T cells and Tregs, sometimes resulting in counterproductive immunosuppression in cancer therapy (Malek & Castro, 2010, Immunity). 3. **Short Half-life:** Recombinant IL-2 has a rapid clearance rate, necessitating frequent dosing and complicating treatment regimens. Interleukin II (60-70) addresses these pain points by offering a more targeted approach to immune modulation. Its smaller size and defined sequence allow for improved pharmacokinetic properties and the potential for conjugation to delivery systems or other bioactive molecules. Furthermore, by focusing on a specific functional domain, it may preferentially activate desired immune subsets, reducing the risk of systemic toxicity and enhancing therapeutic efficacy.
Literature Review
A growing body of literature supports the immunomodulatory potential of IL-2-derived peptides, including the 60-70 region: 1. **Smith (1988, Science):** This foundational study elucidated the structure-function relationship of IL-2, highlighting the importance of discrete peptide regions in receptor binding and signal initiation.
2. **Waldmann (2006, Nat Rev Immunol):** Waldmann reviewed the biology of IL-2 and its receptor, emphasizing the therapeutic implications of modulating IL-2 signaling in cancer and autoimmunity.
3. **Boyman & Sprent (2012, Nat Rev Immunol):** The authors discussed advances in IL-2-based immunotherapy, including the use of IL-2 mutants and fragments to selectively expand effector or regulatory T cells.
4. **Malek & Castro (2010, Immunity):** This review addressed the dual roles of IL-2 in immune activation and tolerance, underscoring the need for selective modulators such as peptide fragments.
5. **Rosenberg et al. (1994, N Engl J Med):** The clinical experience with high-dose IL-2 in metastatic cancer highlighted both the therapeutic potential and the limitations due to toxicity.
6. **Liao et al. (2013, Immunity):** This study provided insights into the structural determinants of IL-2 receptor engagement, supporting the rationale for targeting specific peptide domains.
7. **Tang et al. (2012, J Immunol):** The authors demonstrated that synthetic IL-2 peptides could modulate T-cell responses in vitro and in vivo, paving the way for further translational research. Collectively, these studies establish a strong scientific foundation for the continued investigation of Interleukin II (60-70) as a tool for immune modulation and therapeutic development.
Experimental Data and Results
Experimental studies evaluating Interleukin II (60-70) have focused on its ability to mimic the biological activity of full-length IL-2 while offering improved selectivity and safety profiles. In vitro assays have demonstrated that the peptide can bind to the IL-2Rβγ complex, inducing phosphorylation of downstream signaling molecules such as STAT5 and Akt (Liao et al., 2013, Immunity). This activation leads to enhanced proliferation and survival of CD8+ T cells, with a reduced propensity to expand Tregs compared to native IL-2. Animal models of cancer and autoimmunity have further validated the therapeutic potential of Interleukin II (60-70). For example, Tang et al. (2012, J Immunol) reported that administration of IL-2-derived peptides in murine tumor models resulted in increased infiltration of cytotoxic T lymphocytes (CTLs) into the tumor microenvironment and delayed tumor progression. Importantly, these effects were achieved with minimal systemic toxicity, as evidenced by stable body weight and the absence of vascular leak syndrome. Additional studies have explored the use of Interleukin II (60-70) as a vaccine adjuvant. By enhancing antigen-specific T-cell responses, the peptide has been shown to improve the efficacy of experimental vaccines against infectious diseases and cancer (Boyman & Sprent, 2012, Nat Rev Immunol). These findings support the versatility of Interleukin II (60-70) as both a research tool and a candidate for therapeutic development.
Usage Guidelines and Best Practices
The effective use of Interleukin II (60-70) in research and preclinical applications requires careful consideration of several factors: 1. **Peptide Preparation:** Interleukin II (60-70) should be reconstituted in sterile, endotoxin-free water or appropriate buffer to the desired concentration, typically in the micromolar range for in vitro studies.
2. **Dosing and Administration:** Optimal concentrations vary depending on the experimental system. For T-cell proliferation assays, concentrations ranging from 0.1 to 10 μM are commonly employed. In vivo studies should begin with dose-escalation protocols to determine the minimal effective dose and monitor for adverse effects.
3. **Combination Strategies:** Interleukin II (60-70) may be used alone or in combination with other immunomodulators, checkpoint inhibitors, or vaccine antigens to achieve synergistic effects.
4. **Controls and Validation:** Appropriate negative controls (e.g., scrambled peptide) and positive controls (e.g., recombinant IL-2) are essential for validating the specificity and efficacy of the peptide.
5. **Storage and Stability:** The peptide should be stored at -20°C or lower, protected from light and moisture. Aliquots should be used to minimize freeze-thaw cycles. Researchers are encouraged to consult product datasheets and relevant literature for protocol optimization tailored to their specific experimental needs.
Future Research Directions
While Interleukin II (60-70) has demonstrated promising immunomodulatory activity, several avenues for future research remain: 1. **Structural Optimization:** Rational design of peptide analogs with enhanced receptor selectivity, stability, and bioavailability could further improve therapeutic potential.
2. **Targeted Delivery:** Conjugation of Interleukin II (60-70) to nanoparticles, antibodies, or cell-penetrating peptides may facilitate targeted delivery to specific immune cell subsets or tissues.
3. **Clinical Translation:** Rigorous preclinical studies and early-phase clinical trials are needed to evaluate the safety, pharmacokinet Additional Resources:
Related Websites: APExBIO Technology LLC is a premier provider of Small Molecule Inhibitors/Activators, Compound Libraries, Peptides, Assay Kits, Fluorescent Labels, Enzymes, Modified Nucleotides, mRNA synthesis and various tools for Molecular Biology. We carry a broad product line in over 49 different research areas such as cancer, immunology, neurosciences, apoptosis and epigenetics etc. Based in USA (Houston, Texas), we have been serving the needs of customers across the world.
https://www.apexbt.com/
Research Article: PMC11541594